Latest Regenerative April 14, 2025 News

Subscribe

BioGenCell Nabs FDA Fast Track Designation for Critical Limb Threatening Ischemia Cell Therapy, BGC101

BioGenCell's lead candidate BGC101 receives FDA Fast Track Designation, accelerating development of its personalized cell therapy to prevent amputations in severe CLTI patients.

Allogene Therapeutics Receives Three FDA Fast Track Designations for Lupus, Myositis, and Scleroderma Allogeneic CAR T Therapies

Allogene Therapeutics' dual-targeted CAR T therapy, ALLO-329, receives three FDA Fast Track designations, accelerating development for severe autoimmune conditions including lupus, myositis, and systemic sclerosis.

STEMCELL Technologies nabs $49.9 Million investment from Canadian Government

The funds will help expand and secure Canada's cell based therapy supply chain.

Made Scientific investing $12M to expand stem cell plant in New Jersey

The new Princeton facility will boost BioCentriq's capacity, helping clients accelerate innovative cell therapies from development to commercialization.

First FDA-approved stem cell therapy, Ryoncil, now available. Medicaid coverage coming soon

A significant milestone for the stem cell industry, likely paving the way for future stem cell based therapies.

BrainStorm Cell Therapeutics Gearing Up for Phase 3b Trial of NurOwn, Its ALS Stem Cell Therapy, Submits IND Amendment

The amended IND application moves NurOwn® closer to initiation of the pivotal Phase 3b clinical trial for ALS patients.

Bayer’s BlueRock Therapeutics receives FDA Fast Track Designation for its iPSC OpCT-001 for primary photoreceptor diseases

This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.
x
Subscribe
Subscribe

Stay updated on Regenerative Medicine

Subscribe